Author

P. Moore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Biochemistry· 1 Microbiology· 1 Physiology· 1 Plant Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 6 Organism:human· 5 Assay:proteomics· 3 Research Focus:development & morphogenesis· 2 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

M. Boswell· 3 shared P. Kgagudi· 3 shared V. Ueckermann· 3 shared A. Bodenstein· 2 shared B. E. Lambson· 2 shared B. Lambson· 2 shared F. Ayres· 2 shared G. van den Berg· 2 shared

Activity by Year

2020-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

M. Boswell

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Polymorphisms in HIV-1 nef are associated with plasma concentration of biomarkers of endothelial activation

G. Mezoh, N. Lutchman, E. M. Cave, K. Prigge, C. Worsley, N. Martinson, E. Mayne, B. E. Lambson, P. Moore, N. J. Crowther

This study identifies five HIV-1 nef gene polymorphisms significantly associated with increased plasma ICAM-1 levels, suggesting a link between Nef genetic variation and endothelial activation.

bioRxiv · Oct 10, 2022 · PreprintBiochemistry

SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1

S. Richardson, T. Motlou, M. van der Mescht, B. Lambson, J. Everatt, D. Amoako, A. Van Gottberg, N. Wolter, Z. de Beer, T. Roma de Villiers, A. Bodenstein, G. van den Berg, T. M. Rossouw, M. Boswell, V. Ueckermann, , P. Moore

This study compares the neutralizing antibody responses to SARS-CoV-2 BA.4 and BA.1, finding BA.4 induces more cross-reactive antibodies, suggesting potential benefits for next-generation vaccines.

bioRxiv · Jul 14, 2022 · PreprintImmunology

Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant

S. Richardson, P. Kgagudi, N. P. Manamela, H. Kaldine, E. Venter, T. Pillay, B. E. Lambson, M. van der Mescht, T. Hermanus, Z. de Beer, T. de Villier, A. Bodenstein, G. van den Berg, M. du Pisanie, W. Burgers, , P. Moore

This study shows that convalescent sera and post-vaccination breakthrough infections have reduced neutralization and ADCC activity against SARS-CoV-2 BA.4, despite prior infection with different variants.

bioRxiv · Jul 14, 2022 · PreprintImmunology

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

P. Moore, T. Moyo, T. Hermanus, P. Kgagudi, F. Ayres, Z. Makhado, J. Sadoff, M. Le Gars, G. van Roey, C. Crowther, N. Garrett, L.-G. Bekker, L. Morris, H. Schuitemaker, G. Gray

The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.

bioRxiv · Jun 9, 2021 · PreprintImmunology

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

S.-Y. Lee, D.-K. Ryu, Y. K. Choi, P. Moore, C. A. v. Baalen, r. song, A. S. Tijsma, T. Gwete-Moyo, M. Kim, Y.-I. Kim, C. Kim, J.-I. Kim, K.-S. Kwon

This study evaluates CT-P59's efficacy against SARS-CoV-2 variants, showing reduced in vitro neutralization but effective in vivo therapeutic potential against the B.1.351 variant.

bioRxiv · Apr 27, 2021Microbiology

Performance of generalist hemiparasitic Euphrasia across a phylogenetically diverse host spectrum

M. Brown, P. Moore, A. D. Twyford

This study examines how host species and phylogenetic relationships affect the performance of generalist hemiparasitic plants, finding that performance varies mainly with host traits and some hosts lead to poorer performance over time.

bioRxiv · Mar 25, 2021Plant Biology

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

T. Moyo-Gwete, M. Madzivhandila, Z. Makhado, F. Ayres, D. Mhlanga, B. Oosthuysen, B. Lambson, P. Kgagudi, H. Tegally, A. Iranzadeh, D. Doolabh, L. Tyers, L. Chinhoyi, M. Mennen, S. Skelem, , P. Moore

This study examines antibody responses to the SARS-CoV-2 501Y.V2 variant in patients hospitalized in early 2021, finding robust cross-reactivity against earlier variants and the 501Y.V3 variant.

bioRxiv · Mar 6, 2021 · PreprintImmunology

Development of early-stage type 1 diabetes in germ-free interleukin-10 deficient mice

A. M. Bobe, J. Miyoshi, P. Moore, S. Devkota, V. Leone, K. Martinez, B. R. Theriault, M. W. Musch, C. Wasserfall, M. Atkinson, C. J. Rhodes, E. B. Chang

This study shows that germ-free IL-10 deficient mice develop early pancreatic lymphocytic infiltration and insulin autoantibodies, suggesting gut microbiota protect against T1D pathogenesis.

bioRxiv · Apr 18, 2020 · PreprintPhysiology